Physiotherapy is beneficial in patients with ankylosing spondylitis and while more research is needed, expanding traditional exercise programs to include aerobic and cardiorespiratory components along with patient education may improve outcomes for patients with non-radiographic axial spondyloarthritis as well.
Gregory M. Weiss, M.D.
Swedish researchers writing in Arthritis Research & Therapy earlier this year report that more than half (54%) of patients discontinue their first TNFi treatment within five years and those who remain on a TNF inhibitor treatment receive a lower dose.
DMARDs for autoimmune inflammatory rheumatic diseases have both revolutionized treatment and increased the risk for infections. These patients should be considered for vaccination with the recommendation of a rheumatologist.
In this slideshow, we take a look at vaccination recommendations recently published in the journal Best Practice & Research Clinical Rheumatology .
Availability of new dosages for hydroxychloroquine—a first-line therapy for systemic lupus—may be best for patients, shows a survey conducted by the Lupus Foundation of America.
While significant advances have been made in the treatment of systemic lupus erythematosus (SLE), the highly variable manifestations of the disease make treatment difficult.
A review in the journal Lupus examines treatments for primary and secondary thromboprophylaxis in patients with anti-phospholipid autoantibodies (aPL) and a history of thrombosis, which can affect more than 50 percent of people with systemic lupus erythematosus.
In a review that examines the use of conventional and orphan autoantibodies as biomarkers for diagnosing systemic lupus erythematosus (SLE), researchers say the science is advancing rapidly with the goal of diagnosing lupus earlier than currently done.
Long-term remission in rheumatoid arthritis is rare, but achieving rheumatoid arthritis remission even once can improve function and quality of life, researchers report.
In the September issue of The Lancet Rheumatology, Drs. Janet Pope and Peter C. Taylor review three historical game changers in rheumatoid arthritis treatment.